Asustek Computer Inc (華碩) and its IC design subsidiary ASMedia Technology Inc (祥碩) yesterday said they have agreed to pay VIA Technologies Inc (威盛電子) US$15 million to settle a four-year patent infringement dispute in Taiwan and the US.
Asustek and ASMedia will each shell out US$7.5 million as part of the settlement agreement, the two companies said in separate filings with the Taiwan Stock Exchange.
“The case will not have a significant impact on Asustek’s finance and operations,” Asustek spokesman Nick Wu (吳長榮) said by telephone.
Asustek is considering booking the payment as a one-off expense in last quarter’s financial statements, pending discussions with its accountants, Wu said.
The payment is estimated to reduce Asustek’s earnings per share (EPS) by NT$0.3, based on the company’s 742.76 million outstanding shares.
The settlement is forecast to have a bigger impact on ASMedia, cutting its EPS by NT$3.97, based on its 57.07 million outstanding shares.
ASMedia’s stock price plunged 5.81 percent to close at NT$373 in Taipei trading yesterday.
VIA — an affiliate of HTC Corp (宏達電) — had accused a former executive, Lin Che-wei (林哲偉), and four other former employees who joined ASMedia of disclosing the firm’s confidential technologies on USB 3.0 chips to ASMedia.
VIA in November 2012 accused ASMedia of patent infringement and in 2013 filed a civil lawsuit against Asustek, Asustek CEO Jerry Shen (沈振來) and Lin, and asked for NT$4.13 billion (US$136.5 million) in damages.
Asustek chairman Jonney Shih (施崇棠) in 2013 held a press conference at the Taiwan Stock Exchange, defending the companies and Shen.
VIA chairman Chen Wen-chi (陳文琦) said Shih should state the truth and admit his mistakes.
VIA said in a filing on Monday with the Taiwan Stock Exchange that the company, Asustek and ASMedia reached a settlement on Saturday last week after four years of lawsuits.
“We [VIA, Asustek and ASMedia] are satisfied with the result,” VIA said.
The details of the settlement is protected under a confidentiality agreement, the companies said.
Apple Inc might make one out of four iPhones in India by 2025, JPMorgan & Chase Co analysts said yesterday, as the tech giant moves some production away from China, amid mounting geopolitical tensions and strict COVID-19 lockdowns in the country. JPMorgan expects Apple to move about 5 percent of iPhone 14 production from late this year to India, which is the second-biggest smartphone market in the world after China. It is also estimating that about 25 percent of all Apple products, including Mac, iPad, Apple Watch and AirPods, would be manufactured outside China by 2025 from 5 percent currently. The US company
HEADING SOUTH: The US company chose Kaohsiung as its site as more customers, partners and start-ups have expanded their operations to the southern city Qualcomm Inc yesterday inaugurated a new innovation center in Kaohsiung as it steps up efforts to foster local start-ups and a 5G technology ecosystem in the city, following in the footsteps of its local partners. The US chip company’s move fits the Kaohsiung City Government’s plan to build a semiconductor supply chain within the next five years, highlighted by Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) first chip plant in the city. TSMC plans to start building the factory by the end of this year, and to start production of 28-nanometer and 7-nanometer chips there in 2024. Qualcomm said it had been
SLUMPING DEMAND: Inventory has climbed by up to 12 weeks as suppliers are under mounting pressure to offload excessive reserves, a TrendForce report said The price of DRAM chips is expected to fall at a steeper rate of 13 to 18 percent next quarter, as high inflation continues to weigh on demand for consumer electronics, causing chip inventories to soar, market researcher TrendForce Corp (集邦科技) said yesterday. The downtrend in DRAM prices could extend from a quarterly decline of 10 to 15 percent in the third quarter, the Taipei-based researcher said. “Demand for consumer electronics continued to stagnate during the third quarter, which used to be a high demand season,” TrendForce said in a statement. “During the quarter, memorychip consumption and shipments both showed quarterly
GlaxoSmithKline (GSK) in July made its consumer health products division a separate entity as it transforms into a world-leading biopharmaceutical company. By uniting science, technology and talent, the company is aiming to prevent and treat diseases with innovative vaccines, specialty pharmaceuticals and general medicines. GSK’s headquarters annually invests NT$192 billion (US$6.07 billion) in research and development, focusing on immune science and advanced technologies in human genetics. GSK’s drug and vaccine development focuses on infectious diseases, HIV, oncology and immunology. Investing in clinical trial research each year, GSK also brings drug development to Taiwan. It cooperates with 17 medical institutes and research
RSS